ResMed faces growth doubts ahead of quarterly results
Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash
ResMed (ASX:RMD) reports initial-quarter results in the United States on Thursday, with shares under pressure over slower near-term growth and rising competition. The sleep apnea device maker is still weighed down by August revenue guidance that missed market expectations and a safety-related suspension of its Astral ventilator range.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.